CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Citalopram",CYP2C19,"Minor – result should be considered as may affect medicationresponse"
"Melatonin",CYP1A2,Usual prescribing considerations apply
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antiplatelet drugs,Clopidogrel,CYP2C19,Reduced / inadequate response,CPIC2
Calcineurin inhibitors,Tacrolimus,CYP3A5,Reduced / inadequate response,CPIC3
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,Adverse effects,-
Antiarrhythmics,Flecainide,CYP2D6,Adverse effects,DPWG4
"",Propafenone,CYP2D6,Adverse effects,DPWG4
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9","Increased acenocoumarolsensitivity",
"",Warfarin,"VKORC1CYP2C9",Increased warfarin sensitivity,FDA5
"Antidepressants -other",Moclobemide,CYP2C19,Adverse effects,-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Venlafaxine,CYP2D6,Adverse effects,DPWG4
"Antidepressants -SSRIs",Citalopram,CYP2C19,Adverse effects,CPIC1
Escitalopram,CYP2C19,Adverse effects,CPIC1,
Paroxetine,CYP2D6,Adverse effects,CPIC1,
Sertraline,CYP2C19,Adverse effects,CPIC1,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Antidepressants -tricyclicantidepressants",Amitriptyline,"CYP2D6CYP2C19",Altered response,CPIC6
"",Clomipramine,"CYP2D6CYP2C19",Altered response,CPIC6
"",Desipramine,CYP2D6,Adverse effects,CPIC6
"",Doxepin,"CYP2D6CYP2C19",Altered response,CPIC6
"",Imipramine,"CYP2D6CYP2C19",Altered response,CPIC6
"",Nortriptyline,CYP2D6,Adverse effects,CPIC6
Antidiabetics,Gliclazide,"CYP2C9CYP2C19","Increased therapeutic and/oradverse effects",-
Antiemetics,Ondansetron,CYP2D6,"Increased therapeutic and/oradverse effects",CPIC7
Antifungals - Azoles,Voriconazole,CYP2C19,"Increased therapeutic and/oradverse effects",CPIC8
Antihistamines,Chlorpheniramine,CYP2D6,Adverse effects,-
"",Dexchlorpheniramine,CYP2D6,Adverse effects,-
Antipsychotics,Aripiprazole,CYP2D6,Adverse effects,-
"",Brexpiprazole,CYP2D6,Adverse effects,-
"",Haloperidol,CYP2D6,Adverse effects,-
"",Pimozide,CYP2D6,Adverse effects,
"",Risperidone,CYP2D6,Adverse effects,DPWG4
"",Zuclopenthixol,CYP2D6,Adverse effects,DPWG4
Antitussives,Dextromethorphan,CYP2D6,Altered response,-
Benzodiazepines,Clobazam,CYP2C19,Adverse effects,-
"",Diazepam,CYP2C19,Adverse effects,-
Beta blockers,Metoprolol,CYP2D6,Adverse effects,DPWG4
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,Reduced / inadequate response,CPIC9
Miscellaneous,Atazanavir,CYP3A5,Reduced / inadequate response,-
"",Cyclophosphamide,CYP2C19,Reduced / inadequate response,-
"",Eliglustat,CYP2D6,Adverse effects,TGA10
"",Naltrexone,OPRM1,"Associated with reducedresponse to naltrexone",
"",Proguanil,CYP2C19,Reduced / inadequate response,-
Neurological drugs,Tetrabenazine,CYP2D6,Adverse effects,FDA11
Opioid Analgesics,Morphine,OPRM1,"Associated with increasedtherapeutic and/or adverseeffects to morphine",-
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",FDA12
Esomeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
Lansoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
Omeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
Pantoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
Rabeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"No altered effect predicted bygenotype",-
"",Losartan,CYP2C9,"No altered effect predicted bygenotype",-
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,"No altered effect predicted bygenotype",-
"",Fesoterodine,CYP2D6,"No altered effect predicted bygenotype",-
"",Tolterodine,CYP2D6,"No altered effect predicted bygenotype",-
Anticholinesterases,Donepezil,CYP2D6,"No altered effect predicted bygenotype",-
"",Galantamine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",-
"",Vortioxetine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",-
"Antidepressants -SSRIs",Fluoxetine,"CYP2D6CYP2C9","No altered effect predicted bygenotype",-
"",Fluvoxamine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",CPIC1
Antidiabetics,Glimepiride,CYP2C9,"No altered effect predicted bygenotype",-
"",Glyburide,CYP2C9,"No altered effect predicted bygenotype",-
Antiemetics,Metoclopramide,CYP2D6,"No altered effect predicted bygenotype",-
Antiepileptics,Phenytoin,CYP2C9,"No altered effect predicted bygenotype",CPIC13
Antihistamines,Promethazine,CYP2D6,Adverse effects,-
Antipsychotics,Chlorpromazine,CYP2D6,"No altered effect predicted bygenotype",-
"",Clozapine,CYP1A2,"No altered effect predicted bygenotype",-
"",Olanzapine,CYP1A2,"No altered effect predicted bygenotype",-
"",Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-
Beta blockers,Carvedilol,CYP2D6,"No altered effect predicted bygenotype",-
"",Nebivolol,CYP2D6,"No altered effect predicted bygenotype",-
"",Propranolol,"CYP2D6CYP1A2","No altered effect predicted bygenotype",-
"Glaucoma - ocularpreparations",Timolol,CYP2D6,"No altered effect predicted bygenotype",-
Hypnotics,Melatonin,CYP1A2,"No altered effect predicted bygenotype",-
NSAIDs,Celecoxib,CYP2C9,"No altered effect predicted bygenotype",-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Diclofenac,CYP2C9,"No altered effect predicted bygenotype",-
"",Flurbiprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Ibuprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Indomethacin,CYP2C9,"No altered effect predicted bygenotype",-
"",Mefenamic Acid,CYP2C9,"No altered effect predicted bygenotype",-
"",Meloxicam,CYP2C9,"No altered effect predicted bygenotype",-
"",Piroxicam,CYP2C9,"No altered effect predicted bygenotype",-
Opioid Analgesics,Codeine,"CYP2D6OPRM1","Associated with increasedsensitivity to codeine",CPIC14
"",Hydrocodone,CYP2D6,"No altered effect predicted bygenotype",
"",Oxycodone,CYP2D6,"No altered effect predicted bygenotype",DPWG4
"",Tramadol,CYP2D6,"No altered effect predicted bygenotype",DPWG4
Psychostimulants,Dextroamphetamine,CYP2D6,"No altered effect predicted bygenotype",-
"",Lisdexamfetamine,CYP2D6,"No altered effect predicted bygenotype",-
Statins,Atorvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",-
Fluvastatin,"SLCO1B1CYP2C9","No altered effect predicted bygenotype",-,
Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Simvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",CPIC15,
